Market Overview

UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT

Share:
Related NKTR
Brean Weighs In On Nektar ONZEALD Deal
Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade

In a report published Monday, Jefferies & Company downgraded its rating on Nektar Therapeutics (NASDAQ: NKTR) from Buy to Hold, and lowered its price target from $10.00 to $8.00.

Jefferies noted, “We are downgrading NKTR to Hold from Buy with a new $8 PT based on increased regulatory risks in OIC. Recent FDA scrutiny on CV risks with chronic µ-opioid antagonist use translates to higher approval hurdles potentially involving add'l large CV outcome studies and potentially delaying naloxegol's approval/launch. Thus, NKTR is fairly valued on increased risks.”

Nektar Therapeutics closed on Friday at $8.15.

Latest Ratings for NKTR

DateFirmActionFromTo
Jan 2016Janney CapitalInitiates Coverage onBuy
Mar 2015JefferiesMaintainsBuy
Mar 2015JP MorganMaintainsOverweight

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (NKTR)

View Comments and Join the Discussion!